Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Inamed Breast Implant Panel Nod Helps Boost Stock 31% In March

This article was originally published in The Gray Sheet

Executive Summary

Inamed stock enjoyed a 31% price jump in March to 49-1/2 as a favorable recommendation by an FDA panel reassured investors that the McGhan division's saline breast implants would remain on the market.

You may also be interested in...



B&L Looking To Enter Cosmetic Lens Market Via Wesley Jessen Acquisition

Bausch & Lomb's unsolicited offer for cosmetic contact lens manufacturer Wesley Jessen VisionCare will have to take into account a $20 mil. one-time charge the latter will face if it walks away from a previously announced definitive merger agreement with Ocular Sciences.

Panel Urges McGhan To Recharacterize "Inflated" Complication Rates

Inamed's McGhan Medical unit should eliminate non-significant risks from its risk characterization of saline breast implants as a condition for FDA approval, the agency's General and Plastic Surgery Devices advisory panel concluded March 2 in Gaithersburg, Maryland.

The Race Is On To Launch COVID-19 Antibody Home-Test In The UK

Feature: Public Health England has revealed it is only a week away from approving a COVID-19 antibody test for distribution via Amazon. HBW Insight looks at the race to place the first, government-approved coronavirus home-test on the UK market.

UsernamePublicRestriction

Register

MT013220

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel